The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Multicenter randomized phase II study comparing alternate-day oral therapy using S-1 with the standard regimen as a first-line treatment for patients with locally advanced and metastatic pancreatic cancer: PAN-01 study.
 
Masayuki Sho
No Relationships to Disclose
 
Atsushi Shimizu
No Relationships to Disclose
 
Hiroaki Yanagimoto
No Relationships to Disclose
 
Shoji Nakamori
Research Funding - Eisai (Inst)
 
Takuji Okusaka
Honoraria - Astellas Pharma; Baxter; Bayer Yakuhin; Chugai Pharma; Lilly; Merck Serono; Nippon Kayaku; Nobelpharma; Novartis; Pfizer; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Dainippon Sumitomo Pharma; Lilly; NanoCarrier; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Taiho Pharmaceutical; Zeria Pharmaceutical
Research Funding - AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); GlaxoSmithKline K.K. (Inst); Kowa (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Serono (Inst); Nippon Boehringer Ingelheim (Inst); Nobelpharma (Inst); Novartis (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); Sceti Medical Labo (Inst); Shizuoka Industry (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst); Zeria Pharmaceutical (Inst)
 
Hiroshi Ishii
Honoraria - Ajinomoto; Bayer Yakuhin; Daiichi Sankyo; Hospira; Kyowa Hakko Kirin; Lilly Japan; Mochida Pharmaceutical Co. Ltd.; Nobelpharma; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical
Consulting or Advisory Role - Ono Pharmaceutical
Research Funding - Daiichi Sankyo; Torii Pharmaceutical
 
Masayuki Kitano
No Relationships to Disclose
 
Kazuya Sugimori
No Relationships to Disclose
 
Hiroyuki Maguchi
No Relationships to Disclose
 
Shinichi Ohkawa
Honoraria - Lilly; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Boehringer Ingelheim
 
Hiroshi Imaoka
Honoraria - Taiho Pharmaceutical
 
Daisuke Hashimoto
No Relationships to Disclose
 
Kazuki Ueda
No Relationships to Disclose
 
Hiroko Nebiki
No Relationships to Disclose
 
Tatsuya Nagakawa
No Relationships to Disclose
 
Hiroyuki Isayama
Speakers' Bureau - Taiho Pharmaceutical; Yakult Honsha
Research Funding - Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Yasuhiro Hagiwara
No Relationships to Disclose
 
Yasuo Ohashi
Stock and Other Ownership Interests - Statcom
Honoraria - Sanofi
Consulting or Advisory Role - Chugai Pharma; Eisai; Shionogi; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Takeda; Yakult Honsha
 
Tetsuhiko Shirasaka
Consulting or Advisory Role - Taiho Pharmaceutical
 
Hiroki Yamaue
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Covidien (Inst); Lilly (Inst); OncoTherapy Science (Inst); Otsuka (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)